Brief: Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
02/11/2023 13:05
Nov 2 (Reuters) - Syndax Pharmaceuticals Inc SNDX.O :
* SYNDAX ANNOUNCES RESULTS FROM THE PIVOTAL AGAVE-201 TRIAL
OF
AXATILIMAB IN CHRONIC GRAFT-VERSUS-HOST DISEASE TO BE FEATURED
IN PLENARY SESSION AT THE 65TH ASH ANNUAL MEETING
* SYNDAX PHARMACEUTICALS INC - SYNDAX AND INCYTE INTEND TO
FILE A
BIOLOGICS LICENSE APPLICATION (BLA) BY YEAR-END 2023
Source text for Eikon: ID:nPn5nzjGPa
Further company coverage: SNDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million